Dataset Information

Validation of commercial Mas receptor antibodies for utilization in Western Blotting, immunofluorescence and immunohistochemistry studies.

ABSTRACT: Mas receptor (MasR) is a G protein-coupled receptor proposed as a candidate for mediating the angiotensin (Ang)-converting enzyme 2-Ang (1-7) protective axis of renin-angiotensin system. Because the role of this receptor is not definitively clarified, determination of MasR tissue distribution and expression levels constitutes a critical knowledge to fully understanding its function. Commercially available antibodies have been widely employed for MasR protein localization and quantification, but they have not been adequately validated. In this study, we carried on an exhaustive evaluation of four commercial MasR antibodies, following previously established criteria. Western Blotting (WB) and immunohistochemistry studies starting from hearts and kidneys from wild type (WT) mice revealed that antibodies raised against different MasR domains yielded different patterns of reactivity. Furthermore, staining patterns appeared identical in samples from MasR knockout (MasR-KO) mice. We verified by polymerase chain reaction analysis that the MasR-KO mice used were truly deficient in this receptor as MAS transcripts were undetectable in either heart or kidney from this animal model. In addition, we evaluated the ability of the antibodies to detect the human c-myc-tagged MasR overexpressed in human embryonic kidney cells. Three antibodies were capable of detecting the MasR either by WB or by immunofluorescence, reproducing the patterns obtained with an anti c-myc antibody. In conclusion, although three of the selected antibodies were able to detect MasR protein at high expression levels observed in a transfected cell line, they failed to detect this receptor in mice tissues at physiological expression levels. As a consequence, validated antibodies that can recognize and detect the MasR at physiological levels are still lacking.

SUBMITTER: Burghi V

PROVIDER: S-EPMC5558983 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Validation of commercial Mas receptor antibodies for utilization in Western Blotting, immunofluorescence and immunohistochemistry studies.

Burghi Valeria V Fernández Natalia Cristina NC Gándola Yamila Belén YB Piazza Verónica Gabriela VG Quiroga Diego Tomás DT Guilhen Mario Érica É Felix Braga Janaína J Bader Michael M Santos Robson Augusto Souza RAS Dominici Fernando Pablo FP Muñoz Marina Cecilia MC

PloS one 20170816 8

Mas receptor (MasR) is a G protein-coupled receptor proposed as a candidate for mediating the angiotensin (Ang)-converting enzyme 2-Ang (1-7) protective axis of renin-angiotensin system. Because the role of this receptor is not definitively clarified, determination of MasR tissue distribution and expression levels constitutes a critical knowledge to fully understanding its function. Commercially available antibodies have been widely employed for MasR protein localization and quantification, but ...[more]

PMID: 28813513

Similar Datasets

Project description:Background: The microtubule-associated protein Tau has attracted a diverse and ever-increasing research interest, with the protein being mentioned in the title/abstract of nearly 34,000 PubMed-indexed publications to-date. To facilitate studies into Tau biology and its role in neurodegeneration, a multitude of Tau-targeting antibodies have been developed, with hundreds of distinct antibody clones currently available for purchase. Nevertheless, concerns over antibody specificity and limited understanding of the performance of many of these reagents has hindered research into the protein. Methods: We have characterised the performance and specificity of 53 commercially-available Tau antibodies by Western blot, 35 of which were additionally profiled by immunohistochemistry. Antibodies were tested for their reactivity to both murine and human samples, with supporting data generated by mass spectrometry-based detection. Results: We show that presumed Tau knockout human cells continue to express residual protein, providing evidence of Tau isoforms generated by exon skipping. Our data also reveals that the binding of several antibodies presumed to detect Tau independently of any post translational modifications (i.e. “total” Tau antibodies, as well as an antibody targeting Asp421-cleaved Tau), were partially inhibited by phosphorylation. Moreover, we found that several total and phospho-Tau antibodies cross-reacted with MAP2 isoforms, while the “oligomer-specific” T22 antibody detected monomeric Tau on Western blot. With one exception, the phosphorylation-dependent Tau antibodies tested were found to not cross-react with the unphosphorylated protein. Importantly, several total and isoform-specific Tau antibodies failed to detect Tau expressed at low endogenous levels, highlighting the importance of antibody choice for studying physiological Tau expression, especially in non-neuronal cells and peripheral tissues. Conclusions: We identify Tau antibodies across all categories (total, PTM-dependent and isoform-specific) that can be employed in Western blotting and/or immunohistochemistry applications to reliably detect even low levels of Tau expression with high specificity. This work represents an extensive resource that serves as a point of reference for future studies with respect to anti-Tau antibody use and development.

Dataset Information

Validation of commercial Mas receptor antibodies for utilization in Western Blotting, immunofluorescence and immunohistochemistry studies.

Publications

Validation of commercial Mas receptor antibodies for utilization in Western Blotting, immunofluorescence and immunohistochemistry studies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets